Letter to the Editor: Spinal IL-33/ST2 blockade for gallbladder carcinoma pain - balancing central analgesia with systemic tumor immune microenvironment risks

Abstract

Recently, Ge et al published a study in the World Journal of Gastrointestinal Oncology elucidated the critical role of the spinal interleukin-33/suppression of tumorigenicity 2 (ST2) signaling pathway in gallbladder carcinoma (GBC)-induced chronic pain, providing a highly promising non-opioid analgesic target for advanced refractory cancer pain. We highly commend their establishment of a clinically relevant orthotopic GBC pain model and their profound insights into central sensitization mechanisms. However, before advancing this promising target to clinical translation, the complex “double-edged sword” effects of systemic targeted delivery within tumor biology and systemic immunology must be critically evaluated. This letter highlights that the immunodeficient nude mouse model utilized in the original study fundamentally masks the risk of compromising CD8+ T cell-mediated intrinsic anti-tumor immunity caused by systemic interleukin-33/ST2 blockade. Furthermore, the potential impact of targeted interventions on local dense stromal remodeling in GBC, along with the unknown activation of tumor-intrinsic ST2 signaling, could lead to unexpected pro-tumorigenic consequences. Therefore, we strongly recommend that future translational studies be conducted in immunocompetent syngeneic mouse models, performing head-to-head comparisons between intrathecal targeted delivery and systemic administration. Additionally, utilizing spatial transcriptomics or multiplex immunohistochemistry to clarify the precise cellular localization of ST2 is essential to bridge the gap between neurobiological analgesic mechanisms and the global tumor immune microenvironment.

Keywords: Gallbladder carcinoma; Visceral cancer pain; Interleukin-33/suppression of tumorigenicity 2 signaling pathway; Tumor immune microenvironment; Systemic administration; Translational medicine; Intrathecal delivery; Neuroinflammation

Core Tip: This article highlights a critical translational blind spot in targeting the spinal interleukin-33/suppression of tumorigenicity 2 axis for gallbladder carcinoma-induced pain. While local blockade exhibits analgesic efficacy, systemic administration risks impairing CD8+ T cell-mediated intrinsic anti-tumor immunity - a critical risk fundamentally masked by the original study’s use of athymic nude mice. Furthermore, potential tumor-intrinsic suppression of tumorigenicity 2 activation and stromal remodeling necessitate extreme caution. We strongly advocate that future evaluations utilize immunocompetent syngeneic models to compare intrathecal vs systemic delivery, aiming to safely bridge the gap between analgesic mechanisms and the tumor immune microenvironment.